Brief: Fibrobiologics Advances Patient Dosing For Phase 1/2 Clinical Trial Of Cywc628 For The Treatment Of Diabetic Foot Ulcers
16/06/2026 13:51
BRIEF-Fibrobiologics Advances Patient Dosing For Phase 1/2 Clinical Trial Of Cywc628 For The Treatment Of Diabetic Foot Ulcers June 16 (Reuters) - Fibrobiologics Inc FBLG.O:
FIBROBIOLOGICS ADVANCES PATIENT DOSING FOR PHASE 1/2 CLINICAL TRIAL OF CYWC628 FOR THE TREATMENT OF DIABETIC FOOT ULCERS
FIBROBIOLOGICS INC: CONTINUES TO ADVANCE MANUFACTURING OF CYWC628 TO SUPPORT ONGOING TRIAL ACTIVITY
FIBROBIOLOGICS - TO SHIP SECOND GMP RUN OF CYWC628 TO AUSTRALIA WEEK OF JUNE 15, 2026
Source text: ID:nGNX58Xlv0
Further company coverage: FBLG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts